Symptoms of Acute Bronchitis Accompanied by Coughing
Conditions
Keywords
bronchitis, coughing, children, Ivy, Hedera helix L.
Brief summary
The aims of this study are * Demonstrating superior efficacy of Prospan® Hustenzäpfchen compared to Placebo in children suffering from acute bronchitis accompanied by coughing * Characterisation of safety and tolerability of Prospan® Hustenzäpfchen in comparison with placebo.
Detailed description
After interim analysis of the first part the clinical study will be continued as follows: Double blind, placebo controlled, randomised, multi-centre study with 2-parallel groups for the treatment of acute bronchitis accompanied by coughing in children aged 0 - 6 years to demonstrate efficacy and safety of Prospan® Hustenzäpfchen. For assessment of cough intensity and severity a specific symptom score has been developed, which gathers the child's frequency and severity of coughing and of cough productivity as well as the severity of rhonchi (each symptom will be assessed on a four-point Likert scale ranging from 0 to 3; total score range: 0-12 points). Considering the specificities of the study population and the disease, confirmatory evaluation will be based on the change in the symptom score after the first three consecutive days of treatment as assessed by the investigator.
Interventions
DRUGSuppositories containing Ivy leaves dry extract
Suppositories containing Ivy leaves dry extract
DRUGPlacebo
Suppositories containing no Ivy leaves dry extract
Sponsors
Engelhard Arzneimittel GmbH & Co.KG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Years
Healthy volunteers
No
Inclusion criteria
1. male or female children aged 0 to 6 years 2. acute bronchitis existing not longer than three days and accompanied by coughing 3. symptom rating score of ≥ 5 assessed by the investigator 4. symptom 'frequency of coughing' of ≥ 2 assessed by the investigator 5. the patient's legal representatives must give informed consent in accordance with the supposed will of the patient, after having been informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the risk for patients participating in the study -
Exclusion criteria
1. hypersensitivity to the active ingredient or to any further constituents of the pharmaceutical preparations 2. patients with severe allergies or multiple drug allergies 3. any other pulmonary disease within the last two weeks 4. chronic pulmonary diseases 5. exacerbation of chronic pulmonary disease 6. suspicion of bacterial pulmonary infection 7. fever above 39°C (rectal measurement) -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary outcome measure | 7 days | Effect of treatment as primary variable will be assessed by comparing baseline values to those obtained during visit 2. The primary outcome measure for efficacy will be the relative change in the symptom score between visits 1 and 2. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary variables | 7 days | * absolute change of total symptom score * time to response * compliance, defined by drug accountability * percentage of patients requiring concomitant medication for treatment of cough * rates of premature withdrawal * incidence of Adverse Events |
Countries
Germany
Contacts
Primary ContactManuela Stauss-Grabo, Dr.
Outcome results
None listed